also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Gilead Sciences


Gilead Sciences


The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.


John F. Milligan


Health Care



HQ Location

Foster City, CA

Years on Fortune 500 List




Gilead Sciences is also featured in these fortune lists
Key Financials (last fiscal year)
$ millions% change
Revenues ($M)$32,63931.1%
Profits ($M)$18,10849.6%
Assets ($M)$51,839
Total Stockholder Equity ($M)$18,534
Market Value — as of March 31, 2016 ($M)$124,437
Profit Ratios
Profit as % of Revenues55.5%
Profits as % of Assets34.9%
Profits as % of Stockholder Equity97.7%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)11.91
EPS % Change (from 2014)62.0%
EPS % Change (5 year annual rate)48.3%
EPS % Change (10 year annual rate)39.4%
Total Return
Total Return to Investors (2015)8.7%
Total Return to Investors (5 year, annualized)41.4%
Total Return to Investors (10 year, annualized)22.8%
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

Valeant's New CEO Joe Papa Has a $17 Billion Ultimatum

If he pulls it off, he will make more than all of his peers combined.

Read More →
Gilead Just Paid $125 Million to Nab a Big Market Advantage

The biotech giant can now speed up the drug review process.

Read More →
The Best Stocks to Own If Trump Brings Foreign Cash Home

These tech and pharma companies could cash in on "repatriation."

Read More →